159 related articles for article (PubMed ID: 26468947)
21. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
[TBL] [Abstract][Full Text] [Related]
22. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
23. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium.
Miller K; Morant R; Stenzl A; Zuna I; Wirth M
Urol Int; 2016; 96(1):5-13. PubMed ID: 26068576
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer.
Cao Y; He Y; Chen H; He S; Gu Y; Wang X; Chen B
J BUON; 2018; 23(2):475-481. PubMed ID: 29745095
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
Wisinski KB; Tevaarwerk AJ; Burkard ME; Rampurwala M; Eickhoff J; Bell MC; Kolesar JM; Flynn C; Liu G
Clin Cancer Res; 2016 Jun; 22(11):2659-67. PubMed ID: 27026198
[TBL] [Abstract][Full Text] [Related]
28. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
[TBL] [Abstract][Full Text] [Related]
30. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
32. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
33. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
[TBL] [Abstract][Full Text] [Related]
34. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
35. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Tinker A; Winquist E; Canil C; Moore M; Murray RN; Chi KN
Am J Clin Oncol; 2006 Feb; 29(1):3-7. PubMed ID: 16462494
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
37. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
[TBL] [Abstract][Full Text] [Related]
38. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
39. Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression.
Amsellem-Ouazana D; Beuzeboc P; Peyromaure M; Viellefond A; Zerbib M; Debre B
Ann Oncol; 2004 Mar; 15(3):538. PubMed ID: 14998864
[No Abstract] [Full Text] [Related]
40. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]